Discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results ...

Eli Lilly (LLY) stock is in focus as its Jaypirca cancer drug succeeds in a Phase 3 trial for newly diagnosed patients with ...

Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.

The presentation and publication of the BRUIN CLL-314 trial followed the FDA’s December 3 decision to expand approval for ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...

Lilly’s Jaypirca scores big in first-line CLL/SLL, cutting progression risk by 80% and challenging rival BTK inhibitors.

Jaypirca (pirtobrutinib) improved progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when compared with bendamustine ...

Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...

Noncovalent Bruton tyrosine kinase inhibitors like pirtobrutinib may be a more effective first-line therapy for chronic ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

The FDA has granted traditional approval to pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...